SciVision Biotech Inc.

Total Valuation

SciVision Biotech Inc. carries a market capitalization of 4.07B, placing it among publicly traded companies globally. Its enterprise value stands at 4.67B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

SciVision Biotech Inc. currently has 74.83M shares outstanding.

Valuation Ratios

SciVision Biotech Inc. trades at a trailing price-to-earnings ratio of 32.30. The price-to-sales ratio is 5.91, and the price-to-book ratio stands at 5.78.

Enterprise Valuation

On an enterprise value basis, SciVision Biotech Inc. trades at an EV/EBITDA multiple of 24.61 and an EV/FCF ratio of 20.11. The EV/Sales ratio of 5.27 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 24.61 provides insight into valuation relative to core operating earnings.

Financial Position

SciVision Biotech Inc. maintains a current ratio of 8.17, meaning it holds 8.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 24.50, indicating elevated leverage, while an interest coverage ratio of 23.95 demonstrates strong ability to service its debt obligations.

Financial Efficiency

SciVision Biotech Inc. posts a return on equity of 17.35 and a return on invested capital of 7.24.

Taxes

Over the trailing twelve months, SciVision Biotech Inc. has paid 22.70M in income taxes, reflecting an effective tax rate of 12.27.

Stock Price Statistics

SciVision Biotech Inc.'s stock has declined approximately -40.54645% over the past 52 weeks. The 50-day moving average sits at 56.03, while the 200-day moving average is 72.58.

Income Statement

Over the trailing twelve months, SciVision Biotech Inc. generated 886.62M in revenue and converted that into 162.34M in net income, yielding earnings per share of 2.20. EBITDA reached 189.92M, while operating income came in at 189.92M.

Balance Sheet

SciVision Biotech Inc. holds 1.05B in cash and equivalents against 485.13M in total debt, resulting in a net debt position of -471.71M. Total book value stands at 906.98M, with working capital of 1.25B providing operational flexibility.

Cash Flow

SciVision Biotech Inc. produced 123.99M in operating cash flow over the past twelve months. After subtracting -101.52M in capital expenditures, free cash flow totaled 22.46M - equivalent to 0.31 per share.

Margins

SciVision Biotech Inc. operates with a gross margin of 72.00, reflecting its pricing power and cost economics. The operating margin of 21.42 and net profit margin of 18.31 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

SciVision Biotech Inc.'s most recent stock split took place on October 4, 2021 with a 200:217 split ratio.

Scores

SciVision Biotech Inc. posts an Altman Z-Score of 5.78, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.